Pivotal-Point Tracking GRAIL (GRAL): Cancer Detection Specialist Shows Strong Price Increase Following Positive FDA Signals

GRAIL is developing the Galleri blood test for the early detection of over 50 types of cancer and achieved a revenue of $44.7 million in Q2 2026 (+26% year-over-year growth). The company sold over 61,000 tests in Q2 (+35% test volume). A strategic partnership with Samsung C&T brought in $110 million in investment capital in June, increasing cash reserves to a solid $861.6 million. On September 21, positive preliminary documents from the U.S. health authority FDA triggered a share price jump of around 34%, as they paved the way for formal approval...